Application of nobiletin in pulmonary arterial hypertension cardiopulmonary animal model

The invention discloses an application of nobiletin in a pulmonary arterial hypertension cardiopulmonary animal model, which is characterized in that experimental animals: SD (Sprague Dawley) rats (with the weight of 180-200g) are adaptively fed for one week and then are randomly divided into six groups: a control group (a control group, n = 6), a model group (MCT, n = 6), a sildenafil treatment group (MCT + sildenafil, n = 5) and a nobiletin low-dose treatment group (MCT + nobiletin 1mg/kg); in a treatment group (MCT + nobiletin 5mg/kg, n = 6) with a medium dosage of nobiletin, experimental research finds that the nobiletin has the effect of relieving rat pulmonary arterial hypertension induced by monocrotaline for the first time, and can inhibit PDGF-BB induced pulmonary artery smooth muscle cell proliferation, so that the nobiletin can be used for treating rat pulmonary arterial hypertension induced by monocrotaline. The action mechanism of the nobiletin for relieving the pulmonary arterial hypertension in